13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001920938
Total reported value
$2.7B
$2.7B
73 檔
27.7%
The Q4 2025 SEC filing reveals that Braidwell LP held a total portfolio value of $2.7B, covering 73 public equity positions.
In Q4 2025, Braidwell LP adopted a defensive or profit-taking posture, trimming 32 positions and completely liquidating 20 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including CAI, GH 1.25 02-15-31, EWTX) accounted for 27.7% of total reported equity market value during Q4 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CAI | Caris Life Sciences Inc | Stock-Other | 6.74% | +0.66% | +6.83% | |
| 2 | GH 1.25 02-15-31Bond | Guardant Health Inc | Bond | 6.15% | -3.42% | EXIT | |
| 3 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 4.14% | +0.53% | — | |
| 4 | RGEN 1 12-15-28Bond | Repligen CORP | Bond | 3.54% | -2.68% | — | |
| 5 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 3.41% | -0.77% | -14.63% | |
| 6 | GKOS | Glaukos CORP | Stock-Healthcare | 3.33% | +0.32% | +18.18% | |
| 7 | NEO 0.25 01-15-28Bond | Neogenomics Inc | Bond | 2.87% | -2.44% | — | |
| 8 | NUVL | Nuvalent Inc-a | Stock-Other | 2.64% | -2.39% | EXIT | |
| 9 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 2.62% | -0.07% | -49.37% | |
| 10 | CGON | Cg Oncology Inc | Stock-Other | 2.48% | -2.22% | EXIT | |
| 11 | IRTC 1.5 09-01-29Bond | Irhythm Holdings Inc | Bond | 2.33% | — | -16.13% | |
| 12 | HNGE | Hinge Health Inc-a | Stock-Other | 1.94% | +2.21% | +43.29% | |
| 13 | ALGN | Align Technology Inc | Stock-Healthcare | 1.90% | — | -7.00% | |
| 14 | KOD | Kodiak Sciences Inc | Stock-Other | 1.85% | +0.27% | — | |
| 15 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 1.76% | -1.07% | EXIT | |
| 16 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.75% | -2.63% | EXIT | |
| 17 | NEO | Neogenomics Inc | Stock-Healthcare | 1.74% | +1.26% | +161.57% | |
| 18 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 1.74% | -0.30% | -14.57% | |
| 19 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.71% | +1.32% | -36.60% | |
| 20 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 1.68% | -0.38% | +52.56% | |
| 21 | IRWD 1.5 06-15-26Bond | Ironwood Pharmaceuticals | Bond | 1.61% | — | -34.98% | |
| 22 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.61% | -0.83% | +214.03% | |
| 23 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 1.60% | -0.05% | -38.80% | |
| 24 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 1.59% | +0.20% | -61.16% | |
| 25 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 1.51% | -0.16% | -35.94% | |
| 26 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 1.50% | +0.14% | -29.15% | |
| 27 | BTSG | Brightspring Health Services | Stock-Other | 1.43% | +0.10% | — | |
| 28 | CVS | Cvs Health CORP | Stock-Healthcare | 1.43% | -0.70% | EXIT | |
| 29 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.39% | -1.34% | EXIT | |
| 30 | NRIX | Nurix Therapeutics Inc | Stock-Other | 1.32% | +0.24% | — | |
| 31 | VERA | Vera Therapeutics Inc | Stock-Other | 1.27% | +0.20% | +66.00% | |
| 32 | IRTC | Irhythm Holdings Inc | Stock-Healthcare | 1.23% | +0.48% | -3.76% | |
| 33 | TMDX | Transmedics Group Inc | Stock-Healthcare | 1.23% | +0.41% | -10.22% | |
| 34 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 1.14% | -0.94% | EXIT | |
| 35 | ILMN | Illumina Inc | Stock-Healthcare | 1.13% | -0.94% | EXIT | |
| 36 | KYMR | Kymera Therapeutics Inc | Stock-Other | 1.13% | +0.66% | +64.17% | |
| 37 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 1.11% | -0.80% | EXIT | |
| 38 | PEN | Penumbra Inc | Stock-Healthcare | 1.10% | -1.15% | EXIT | |
| 39 | MBX | Mbx Biosciences Inc | Stock-Other | 1.03% | -0.04% | — | |
| 40 | RAPT | Rapt Therapeutics Inc | Stock-Other | 1.01% | — | — | |
| 41 | CDNA | Caredx Inc | Stock-Other | 0.96% | +0.03% | -27.38% | |
| 42 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.92% | -0.26% | -45.86% | |
| 43 | ✓ | Engene Holdings Inc | Stock-Other | 0.90% | -0.56% | EXIT | |
| 44 | LEGN | Legend Biotech Corp-adr | Stock-Other | 0.90% | — | -28.91% | |
| 45 | MRVI | Maravai Lifesciences Hldgs-a | Stock-Other | 0.87% | +1.04% | — | |
| 46 | DHR | Danaher CORP | Stock-Healthcare | 0.87% | +0.18% | -61.78% | |
| 47 | ARGX | Argenx Se - Adr | Stock-Healthcare | 0.83% | -1.46% | -59.25% | |
| 48 | NTRA | Natera Inc | Stock-Healthcare | 0.82% | -0.06% | — | |
| 49 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 0.81% | -0.05% | +6.81% | |
| 50 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.74% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | EWTX | Edgewise Therapeutics Inc | +1.6% | — | Unchanged |
| 2 | GKOS | Glaukos CORP | +1.4% | +18.18% | Add |
| 3 | NEO | Neogenomics Inc | +1.3% | +161.57% | Add |
| 4 | CLDX | Celldex Therapeutics Inc | +1.2% | +214.03% | Add |
| 5 | FULC | Fulcrum Therapeutics Inc | +1.1% | +1294.71% | Add |
| 6 | VERA | Vera Therapeutics Inc | +0.9% | +66.00% | Add |
| 7 | DNTH | Dianthus Therapeutics Inc | +0.7% | +52.56% | Add |
| 8 | KYMR | Kymera Therapeutics Inc | +0.7% | +64.17% | Add |
| 9 | HNGE | Hinge Health Inc-a | +0.6% | +43.29% | Add |
| 10 | RGEN 1 12-15-28Bond | Repligen CORP | +0.5% | — | Unchanged |
| 11 | CVS | Cvs Health CORP | +0.5% | +28.64% | Add |
| 12 | ✓ | Engene Holdings Inc | +0.4% | +38.17% | Add |
| 13 | SYRE | Spyre Therapeutics Inc | +0.4% | -36.60% | Trim |
| 14 | ALGN | Align Technology Inc | +0.4% | -7.00% | Trim |
| 15 | SRZN | Surrozen Inc | +0.3% | +235.71% | Add |
| 16 | BMRN | Biomarin Pharmaceutical Inc | +0.3% | +13.92% | Add |
| 17 | NEO 0.25 01-15-28Bond | Neogenomics Inc | +0.3% | — | Unchanged |
| 18 | TECX | Tectonic Therapeutic Inc | +0.3% | +25.87% | Add |
| 19 | DRUG | Bright Minds Biosciences Inc | +0.3% | +6.81% | Add |
| 20 | ACAD | Acadia Pharmaceuticals Inc | +0.2% | -14.57% | Trim |
| 21 | ✓ | Zura Bio LTD | +0.2% | +28.61% | Add |
| 22 | CAI | Caris Life Sciences Inc | +0.2% | +6.83% | Add |
| 23 | MRVI | Maravai Lifesciences Hldgs-a | +0.2% | — | Unchanged |
| 24 | IRTC | Irhythm Holdings Inc | +0.1% | -3.76% | Trim |
| 25 | TMDX | Transmedics Group Inc | +0.1% | -10.22% | Trim |
| 26 | NUVL | Nuvalent Inc-a | 0% | -18.91% | Trim |
| 27 | PEN | Penumbra Inc | 0% | -22.17% | Trim |
| 28 | CDNA | Caredx Inc | 0% | -27.38% | Trim |
| 29 | KIDS | Orthopediatrics CORP | 0% | -0.67% | Trim |
| 30 | LUNG | Pulmonx CORP | 0% | — | Unchanged |
| 31 | HROW | Harrow Inc | 0% | -13.76% | Trim |
| 32 | DYN | Dyne Therapeutics Inc | -0.1% | -45.86% | Trim |
| 33 | TMO | Thermo Fisher Scientific Inc | -0.1% | -29.15% | Trim |
| 34 | ADPT | Adaptive Biotechnologies | -0.2% | -57.61% | Trim |
| 35 | IRTC 1.5 09-01-29Bond | Irhythm Holdings Inc | -0.2% | -16.13% | Trim |
| 36 | XNCR | Xencor Inc | -0.2% | -63.16% | Trim |
| 37 | ISRG | Intuitive Surgical Inc | -0.2% | -35.94% | Trim |
| 38 | NBIX | Neurocrine Biosciences Inc | -0.3% | -14.63% | Trim |
| 39 | APGE | Apogee Therapeutics Inc | -0.3% | -60.03% | Trim |
| 40 | KNSA | Kiniksa Pharmaceuticals International, plc | -0.3% | -51.21% | Trim |
| 41 | CSTL | Castle Biosciences Inc | -0.3% | -78.46% | Trim |
| 42 | INSP | Inspire Medical Systems Inc | -0.4% | -38.80% | Trim |
| 43 | RGEN | Repligen CORP | -0.4% | -58.20% | Trim |
| 44 | IRWD 1.5 06-15-26Bond | Ironwood Pharmaceuticals | -0.6% | -34.98% | Trim |
| 45 | ORKA | Oruka Therapeutics Inc | -0.7% | -93.87% | Trim |
| 46 | SLNOEUR | Soleno Therapeutics Inc | -0.8% | -7.34% | Trim |
| 47 | ARGX | Argenx Se - Adr | -0.8% | -59.25% | Trim |
| 48 | LEGN | Legend Biotech Corp-adr | -0.9% | -28.91% | Trim |
| 49 | DHR | Danaher CORP | -1% | -61.78% | Trim |
| 50 | KRYS | Krystal Biotech Inc | -1.1% | -61.16% | Trim |
According to official SEC Form 13F filings, Braidwell LP reported a total U.S. public equity portfolio value of $2.7B across 73 disclosed positions in Q4 2025.
During Q4 2025, Braidwell LP's top holdings by market value included CAI (6.7%)、GH 1.25 02-15-31 (6.2%)、EWTX (4.1%). The largest single position, CAI, represented 6.7% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
KOD
市值: $58.0M
Top Position Liquidated / Trimmed
NVCR 0 11-01-25
前期市值: $210.0M
In Q4 2025, Braidwell LP made 88 total portfolio adjustments, initiating 20 new buys, adding to 16 positions, trimming 32 holdings, and fully liquidating 20 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.